Navigating the Complexities of Life Sciences: Tory Agnich’s Vision for Proactive Risk Management

Liberty Mutual’s Tory Agnich is bringing a life-long fascination with science into her new role as a middle market life sciences leader.
By: | November 11, 2024

Life science professionals operate in a thrilling atmosphere. They are working to create scientific breakthroughs that can be life-changing for those who need their products. They also must have the spirit of bold entrepreneurs, who navigate regulatory hurdles as they compete for the best talent and strive to find the funding that can make or break them.

Into this field happily steps Liberty Mutual’s Tory Agnich, a 24-year veteran of life sciences risk management and risk transfer. “Science has always been my passion, especially how laboratory research can translate into real world advancements in health care, improving and saving the lives of humans and animals,” Agnich said.

“That passion drove me to major in biology with a concentration in genetics and minor in neuroscience, with thesis work in the molecular basis of learning and memory and neural plasticity.”

She well knows the pressures her clients face. “There are high standards for companies involved in developing products critical to the health care of humans and animals,” she said.

“Any misstep can delay FDA or other regulatory approval and market entry. It is critical to mitigate the potential for a holdup and to manage its impact. While life sciences companies always faced tremendous pressure to quickly move from concept to product, that pressure has grown significantly in the pandemic’s aftermath, making proactive risk management even more important.”

Agnich’s team serves companies performing research and developing products to diagnose, cure, treat, mitigate and/or prevent disease in humans or animals.It serves the two largest sub-industries, medical devices and pharmaceuticals, as well as firms in growing segments, including digital health, analytical abs (including personalized medicine), human cell and tissue-products, and dietary supplements.

“We also partner with companies providing products and services to this core, including contract research organizations, contract manufacturing organizations, clinical trial support services, research institutes and distributors. My life sciences practice adds value throughout the lifecycle of these companies, from start-ups to fully operationalized firms with $2 billion in product or service revenue,” Agnich said.

The clients of Agnich and her team face plenty of challenges in the aforementioned areas of talent, funding and regulation. But the task before her and her team has challenges of its own.

“Our success is dependent on our ability to translate and communicate that value, where it resonates with each company. Risk management, insurance policy language, legal liability exposures are all complex and nuanced for every company. They often matter most when a company is served with a claim, and we have the dedicated, experienced life sciences claims team in place that can deliver on our promise. But we also want to take all of that experience and insight and translate it into proactive up front risk mitigation and policy coverage,” she said. &


Tory Agnich has been selected as a 2025 Risk & Insurance® Executive to Watch. To see the other executives selected this year, visit here.

Dan Reynolds is editor-in-chief of Risk & Insurance. He can be reached at [email protected].

More from Risk & Insurance